Description
LINATAB M 2.5/850 is a combination antidiabetic tablet containing linagliptin 2.5 mg (a DPP-4 inhibitor) and metformin hydrochloride 850 mg (a biguanide). Designed to manage type 2 diabetes mellitus, linagliptin enhances insulin secretion and reduces glucagon release by prolonging incretin hormone activity, while metformin lowers blood glucose by suppressing hepatic glucose production and improving insulin sensitivity5. This dual-action formulation is prescribed alongside diet and exercise, typically taken twice daily with meals to minimize gastrointestinal side effects like nausea or diarrhea35. It is contraindicated in renal impairment, severe liver disease, or conditions predisposing to lactic acidosis, and requires cautious use in elderly patients or those on concomitant insulin/secretagogues to avoid hypoglycemia5. Dosage adjustments may be necessary for patients already on metformin or when combined with other glucose-lowering agents
.jpeg)
.jpeg)
.webp)
 100 IU 3 ML.webp)
.webp)
.jpeg)
.jpg)
.webp)
.jpeg)
.jpg)
 400MG.jpg)
.jpg)
.jpg)
.jpg)
.png)
.jpg)
.jpg)
.jpg)
Change Language